Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MEXT to Set Up “Shared Facilities” for Drug Discovery, Push Open Innovation
April 5, 2016
-
BUSINESS Ex-Pfizer Japan Exec Matsumori to Lead Takeda-Teva JV
April 4, 2016
-
BUSINESS Sakigake: Now and Future (5) - BioCryst’s BCX7353 Would Be Japan’s 1st Drug for Preventing Angioedema Attacks
April 4, 2016
-
BUSINESS Daiichi Sankyo Eyes V-Shaped Recovery from Olmesartan Patent Cliff: 5-Year Plan
April 1, 2016
-
BUSINESS HPV Vaccine Makers, Govt to Face Class-Action Suit; MSD Says Plaintiffs’ Claim Unfounded
March 31, 2016
-
INTERVIEW Takeda Linking Arms with a “Reborn” Teva, Sees Turning Point in Market as an Opportunity: Japan Biz Chief Iwasaki
March 30, 2016
-
BUSINESS Mylan Japan Offers Severance Package for 110 Sales Reps
March 29, 2016
-
BUSINESS Torii Looks to Ramp Up Sales in Allergen Sector, Expand Indications for Sublingual Therapies
March 28, 2016
-
BUSINESS MSD Going Full Out for Sakigake-Designated Pembrolizumab, Poised to Bolster Oncology Force
March 25, 2016
-
BUSINESS Hengrui to Apply for Sakigake Designation; Develop New Drugs Alongside Generics in Japan
March 24, 2016
-
ACADEMIA Positioning of Abraxane and Anti-PD-1 Antibodies Will Be Focus of Interest in Revised Guidelines for Gastric Cancer
March 23, 2016
-
BUSINESS Jitsubo Aims to Launch Peptide Generic Drugs Using Its Unique Technologies
March 22, 2016
-
ORGANIZATION FPMAJ Braced for Thorny Path Ahead Even If Sales Tax Postponed, Revenue Falls Would Weigh on Industry: Chief
March 18, 2016
-
ORGANIZATION Discuss Role of Drugs in Overall Social Security System: Full Interview with FPMAJ Pricing Affairs Chief
March 18, 2016
-
REGULATORY Whether to Draw Line between 15 Billion and 100 Billion Yen Sales Thresholds for Re-Pricing Will Hold Key: Kamoya, Nakai
March 17, 2016
-
ACADEMIA It’s Time to Discuss Restart of HPV Vaccine Promotion, Panel Chief Says as Personal View
March 16, 2016
-
REGULATORY Sales Thresholds for Re-Pricing Rule to Be Key Point of Future Discussions: MHLW Pharma Management Director
March 15, 2016
-
REGULATORY No Licensing Deal Clinched for First AMED-Backed Drug Seed
March 14, 2016
-
BUSINESS Ono Beefing Up Organization for Safe Use of Opdivo, Eyes Larger Cancer Sales Force
March 11, 2016
-
ORGANIZATION “Huge-Seller” Re-Pricing Eroding Predictability of Japanese System: FPMAJ’s Kamoya
March 10, 2016
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…